<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05102370</url>
  </required_header>
  <id_info>
    <org_study_id>21-268</org_study_id>
    <nct_id>NCT05102370</nct_id>
  </id_info>
  <brief_title>A Study of Enasidenib in People With Clonal Cytopenia of Undetermined Significance</brief_title>
  <official_title>A Pilot Study of Enasidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study researchers think that a drug called enasidenib may help people with clonal cytopenia&#xD;
      of undetermined significance (CCUS) because the drug blocks the mutated IDH2 protein, which&#xD;
      may improve blood cell counts. The purpose of this study is to find out whether enasidenib is&#xD;
      a safe and effective treatment for CCUS.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 6, 2021</start_date>
  <completion_date type="Anticipated">October 6, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 6, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best Response</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>The primary objective is to estimate the rate of hematologic improvement. The endpoint is evaluated as the best response at any point in up to 18 months of treatment with enasidenib.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Clonal Cytopenia of Undetermined Significance</condition>
  <condition>CCUS Clonal Cytopenia of Undetermined Significance</condition>
  <arm_group>
    <arm_group_label>Participants with CCUS with mutations in IDH2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will have CCUS with mutations in IDH2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enasidenib</intervention_name>
    <description>Study participants will receive enasidenib 100 mg daily for 18 months. Participants will continue treatment with enasidenib until confirmed progression to AML or MDS, development of unacceptable toxicity, or suspicion of disease progression, provided the patient is deriving clinical benefit, which will be determined at the discretion of the principal investigator.</description>
    <arm_group_label>Participants with CCUS with mutations in IDH2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 years at the time of signing the informed consent form.&#xD;
&#xD;
          -  Willing and able to adhere to the study visit schedule and other protocol&#xD;
             requirements.&#xD;
&#xD;
          -  Unexplained cytopenia for at least 6 months. Cytopenia is defined as the presence of&#xD;
             ≥1 blood count indexes below the following thresholds:&#xD;
&#xD;
          -  Hgb &lt;10 g/dL&#xD;
&#xD;
          -  ANC &lt;1.8 × 10^9/L&#xD;
&#xD;
          -  Platelets &lt;100 × 10^9/L&#xD;
&#xD;
          -  Results of bone marrow biopsy within 1 month of study entry (screening bone marrow&#xD;
             biopsy) must not indicate hematologic disease.&#xD;
&#xD;
          -  IDH2 gene mutation (R140 or R172), confirmed by droplet digital PCR (ddPCR) testing,&#xD;
             at a frequency &gt;2%.&#xD;
&#xD;
          -  ECOG performance status of 0-2.&#xD;
&#xD;
          -  Adequate organ function, defined as:&#xD;
&#xD;
               -  Serum aspartate aminotransferase/serum glutamic oxaloacetic transaminase&#xD;
                  (AST/SGOT) and alanine aminotransferase (ALT/SGPT) ≤3x upper limit of normal&#xD;
                  (ULN), unless the subject has Gilbert's syndrome.&#xD;
&#xD;
               -  Serum total bilirubin &lt;1.5x ULN. Higher levels are acceptable if these can be&#xD;
                  attributed to ineffective erythropoiesis. In these cases, approval from the study&#xD;
                  Principal Investigator is required.&#xD;
&#xD;
               -  Creatinine clearance greater than 50 mL/min based on the Cockroft-Gault&#xD;
                  glomerular filtration rate estimation.&#xD;
&#xD;
          -  Folate, B12, serum iron, serum ferritin, total iron binding capacity, haptoglobin and&#xD;
             peripheral smear within normal limits&#xD;
&#xD;
          -  Women of childbearing potential may participate provided they have a negative serum&#xD;
             pregnancy test at screening and a negative serum or urine pregnancy test within 72 h&#xD;
             of starting treatment.&#xD;
&#xD;
          -  Women of childbearing potential (WOCBP) and males with partners who are WOCBP must&#xD;
             agree to abstain from sexual intercourse or to use 1 highly effective form of&#xD;
             contraception during the study and for at least 4 months following the last dose of&#xD;
             enasidenib. Males with partners who are WOCBP must agree to use a barrier method.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active malignancy defined as &gt;1-cm disease on most recent CT scan in the past 6 months&#xD;
             or recent history of cancer (i.e. within the past 5 years) with &gt;50% chance of cancer&#xD;
             recurrence in the next 5 years.&#xD;
&#xD;
          -  Current or prior history of hematologic malignancy.&#xD;
&#xD;
          -  Therapy (including maintenance therapy) for solid-tumor malignancy within the last 6&#xD;
             months.&#xD;
&#xD;
          -  Known dysphagia, short-gut syndrome, gastroparesis, or other conditions that limit the&#xD;
             ingestion or gastrointestinal absorption of drugs administered orally.&#xD;
&#xD;
          -  Active uncontrolled systemic fungal, bacterial, or viral infection (defined as ongoing&#xD;
             signs/symptoms related to the infection without improvement despite appropriate&#xD;
             antibiotics, antiviral therapy, and/or other treatment).&#xD;
&#xD;
          -  Positive direct Coombs test&#xD;
&#xD;
          -  Evidence of hypersplenism on physical exam&#xD;
&#xD;
          -  Pregnant or lactating (women).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eytan Stein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eytan Stein, MD</last_name>
    <phone>646-608-3749</phone>
    <email>SteinE@mskcc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Martin Tallman, MD</last_name>
    <phone>646-608-3754</phone>
    <email>TallmanM@mskcc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic (Data Collection Only)</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mrinal Patnaik, MD</last_name>
      <phone>507-284-2511</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University (Data Collection and Specimen Analysis)</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kelly Bolton, MD, PhD</last_name>
      <phone>314-273-5711</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering at Basking Ridge (All Protocol Activities)</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eytan Stein, MD</last_name>
      <phone>646-608-3749</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Monmouth (All protocol activities)</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eytan Stein, MD</last_name>
      <phone>646-608-3749</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Bergen (Limited protocol activities)</name>
      <address>
        <city>Montvale</city>
        <state>New Jersey</state>
        <zip>07645</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eytan Stein, MD</last_name>
      <phone>646-608-3749</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Suffolk-Commack (Limited protocol activities)</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eytan Stein, MD</last_name>
      <phone>646-608-3749</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Westchester (All Protocol Activities)</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eytan Stein, MD</last_name>
      <phone>646-608-3749</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center (All Protocol Activities)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eytan Stein, MD</last_name>
      <phone>646-608-3749</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Nassau (Limited protocol activities)</name>
      <address>
        <city>Rockville Centre</city>
        <state>New York</state>
        <zip>11553</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eytan Stein, MD</last_name>
      <phone>646-608-3749</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic (Data Collection Only)</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bhumika Patel, MD</last_name>
      <phone>216-444-2200</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ohio State University (Data Collection Only)</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Uma Borate, MBBS</last_name>
      <phone>614-293-3196</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University (Data Collection Only)</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Brian Druker, MD</last_name>
      <phone>503-494-8311</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 20, 2021</study_first_submitted>
  <study_first_submitted_qc>October 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2021</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CCUS</keyword>
  <keyword>Clonal Cytopenia of Undetermined Significance</keyword>
  <keyword>Enasidenib</keyword>
  <keyword>21-268</keyword>
  <keyword>Memorial Sloan Kettering Cancer Center</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Leukopenia</mesh_term>
    <mesh_term>Thrombocytopenia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

